Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake”

  • 40 Accesses

This is a preview of subscription content, log in to check access.


  1. 1.

    Werner RA, Bundschuh RA, Bundschuh L et al (2019) Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01375-w

  2. 2.

    Cysouw M, Jansen BHE, Yaqub MM et al (2019) Letter to the Editor Re: semiquantitative parameters in PSMA-targeted PET Imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01438-y

  3. 3.

    Jansen BHE, Yaqub M, Voortman J et al (2019) Simplified methods for quantitation of 18F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. https://doi.org/10.2967/jnumed.119.227520

  4. 4.

    Rowe SP, Campbell SP, Mana-Ay M et al (2019) Prospective evaluation of PSMA-targeted 18F-DCFPyL in men with biochemical failure after radical prostatectomy for prostate cancer. J Nucl Med. https://doi.org/10.2967/jnumed.119.226514

  5. 5.

    Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA (2019) Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856–863

  6. 6.

    Radwan N, Phillips R, Ross A et al (2017) A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate cancer (ORIOLE). BMC Cancer 17:453

  7. 7.

    Gaertner FC, Halabi K, Ahmadzadehfar H et al (2017) Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget 8:55094–55103

  8. 8.

    Sahakyan K, Li X, Lodge MA et al (2019) Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: intrapatient and interpatient variability of normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01376-9

  9. 9.

    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ (2017) German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90

  10. 10.

    Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S (2018) [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825–833

  11. 11.

    Sethekge M, Bruchertseifer F, Knoesen O et al (2019) 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138

  12. 12.

    Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ (2018) Effects of fasting on 18F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake. J Nucl Med 59:1081–1084

  13. 13.

    Kulkarni HR, Singh A, Langbein T et al (2018) Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol 91:20180308

  14. 14.

    Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M (2019) Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nucl Med. https://doi.org/10.2967/jnumed.119.228072

  15. 15.

    Kotasidis FA, Tsoumpas C, Rahmim A (2014) Advanced kinetic modelling strategies: towards adoption in clinical PET imaging. Clin Transl Imaging 2:219–237

  16. 16.

    Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832–842

Download references

Author information

Correspondence to Ralph A. Bundschuh.

Ethics declarations

Conflict of Interest

MGP is a co-inventor on a US patent covering 18F-DCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. SPR is a consultant to Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. MAG has served as a consultant to Progenics Pharmaceuticals. SPR, MAG, KJP, and MGP receive research funding from Progenics Pharmaceuticals. No other potential conflicts of interest relevant to this article exist.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Werner, R.A., Pienta, K.J., Pomper, M.G. et al. Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake”. Mol Imaging Biol 22, 19–21 (2020). https://doi.org/10.1007/s11307-019-01452-0

Download citation